| Ticker | Mentions | Stance | Conv | Entry | P&L YTD | Theme | Thesis (click to expand) | Mentioned | Src |
|---|---|---|---|---|---|---|---|---|---|
| TCNNF | ×1 | LONG | MED | $8.50 | Other | Trulieve Cannabis Corp. benefits from rescheduling via tax savings and medical legitimacy. Financial improvement fuels investor sentiment, amplifying price gains. TCNNF rose over 20% and may trend higher with policy implementation. Execution challenges; regulatory uncertainties persist. | Apr 22 | ||
| MSOS | ×1 | LONG | MED | $5.25 | Healthcare | Cannabis rescheduling to Schedule III is expected, allowing business expense deductions and medical recognition. This improves profitability and legal standing for U.S. cannabis companies, driving ETF appreciation. MSOS rallied 25% on news and may continue upward as rescheduling finalizes. Rescheduling delay or failure; structural industry headwinds remain. | Apr 22 | ||
| GTBIF | ×1 | LONG | MED | $8.25 | Other | Rescheduling enables tax deductions for Green Thumb Industries, lowering effective tax rate. Improved net income enhances stock attractiveness amid sector rally. GTBIF up over 20% on news, with further gains likely from policy shift. Company-specific operational issues; rescheduling may not materialize. | Apr 22 | ||
| CURLF | ×1 | LONG | MED | $3.90 | Other | Curaleaf Holdings gains from rescheduling through tax relief and federal recognition. Enhanced earnings potential drives stock revaluation amid sector optimism. CURLF up over 20% on news, with room for growth if policy enacted. Rescheduling delays; industry oversupply pressures. | Apr 22 |